Zoetis (NYSE:ZTS) Sets New 12-Month Low – Here’s What Happened

Zoetis Inc. (NYSE:ZTS) shares reached a new 52-week low on Friday . The stock traded as low as $113.29 and last traded at $113.4770, with a volume of 3404316 shares changing hands. The stock had previously closed at $116.63.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Bank of America upped their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm’s 50-day moving average is $123.62 and its two-hundred day moving average is $129.58. The company has a market cap of $47.90 billion, a P/E ratio of 18.85, a PEG ratio of 1.78 and a beta of 0.95.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the business posted $1.40 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Hedge Funds Weigh In On Zoetis

A number of large investors have recently bought and sold shares of ZTS. CIBC Asset Management Inc boosted its stake in Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares in the last quarter. Ninety One UK Ltd increased its stake in Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after buying an additional 183,686 shares during the period. Quilter Plc raised its holdings in shares of Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after acquiring an additional 40,615 shares in the last quarter. Finally, Swedbank AB grew its position in Zoetis by 60.4% in the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after acquiring an additional 917,598 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.